To explore barriers to anticoagulation in older adults with atrial fibrillation (AF) at high risk of stroke and to identify opportunities for interventions that might increase use of oral anticoagulants (OACs). DESIGN: Retrospective cohort study. SETTING: Two large community-based AF cohorts. PARTICIPANTS: Individuals with ischemic stroke surviving hospitalization (N = 1,405, mean age 79). MEASUREMENTS: Using structured chart review, reasons for nonuse of OAC were identified, and 1-year poststroke survival was assessed. Logistic regression was used to identify correlates of OAC nonuse. RESULTS: Median CHA 2 DS 2 -VASc score was 5, yet 44% of participants were not prescribed an OAC at discharge. The most-frequent (nonmutually exclusive) physician reasons for not prescribing OAC included fall risk (26.7%), poor prognosis (19.3%), bleeding history (17.1%), participant or family refusal (14.9%), older age (11.0%), and dementia (9.4%). Older age (odds ratio (OR) = 8.96, 95% confidence interval (CI) = 5.01-16.04 for aged ≥85 vs <65) and disability (OR = 12.58, 95% CI = 5.82-27.21 for severe vs no deficit) were the most-important independent predictors of nonuse of OACs. By 1 year, 42.5% of those not receiving an OAC at discharge had died, versus 19.1% of those receiving an OAC (P < .001), far higher than recurrent stroke rates. CONCLUSION: Despite very high stroke risk, more than 40% of participants were not discharged with an OAC. Dominant reasons included fall risk, poor prognosis, older age, and dementia. These individuals' high 1-year mortality rate confirmed their high level of comorbidity. To improve anticoagulation decisions and outcomes in this population, future research should focus on strategies to mitigate fall risk, improve assessment of risks and benefits of anticoagulation in individuals with AF, and determine whether newer anticoagulants are safer in complex elderly and frail individuals. J Am Geriatr Soc 65:241-248, 2017.
P rior ischemic stroke is one of the most important risk factors for recurrent ischemic stroke in individuals with atrial fibrillation (AF). 1 Oral anticoagulant (OAC) therapy can reduce the risk of ischemic stroke by two-thirds in individuals with AF with prior ischemic stroke. 2 Despite this, a large proportion of individuals with AF are not prescribed an OAC after ischemic stroke. 3 There is a lack of understanding of the reasons why OAC therapy is not prescribed for such individuals at very high risk of recurrent ischemic stroke. Previous studies primarily included individuals at lower stroke risk without prior stroke 4 and were limited by small sample sizes. [4] [5] [6] Greater insights into nonuse of OAC therapy in high-risk secondary prevention populations may enable targeted interventions to increase appropriate use of OAC therapy in suitable candidates, including individuals with AF without prior stroke who are otherwise at high stroke risk. The current study explored the reasons for not prescribing OAC therapy after acute ischemic stroke in two large community-based cohorts of individuals with AF.
METHODS

Study Design
This is a report on the clinical course of all individuals sustaining an ischemic stroke during follow-up of two separate cohorts of individuals with AF: Anticoagulation and Risk factors in Atrial Fibrillation (ATRIA) and ATRIA Cardiovascular Research Network (CVRN).
Population
The first cohort, the ATRIA nonvalvular AF cohort, has been described in detail previously. 7 In brief, Kaiser Permanente of Northern California members aged 18 and older with two or more outpatient AF diagnoses (International Classification of Diseases, Ninth Revision (ICD-9) code 427.31) or one outpatient AF diagnosis with electrocardiographic validation between July 1, 1996, and December 31, 1997, were included, resulting in a 13,559-member cohort. Individuals with mitral stenosis or an aortic or mitral valve replacement were excluded. Follow-up continued through September 2003. Clinical data were collected from inpatient, outpatient, laboratory, pharmacy, and administrative databases, as well as a longitudinal diabetes registry. [7] [8] [9] The current study focused on cohort members who sustained an ischemic stroke during followup. Potential stroke events were identified using hospitalization and billing databases using ICD-9 codes for ischemic stroke in the primary discharge position (ICD-9 codes: 433.00, 433.01, 433. 10 ). Medical records of potential events were abstracted using a formal protocol, with two physicians adjudicating each event and a third available to resolve disagreements. In rare cases, a consultant neurologist provided the final diagnosis. Individuals who presented to non-Kaiser institutions with stroke were identifiable in Kaiser Permanente databases. A valid ischemic stroke was defined as the sudden onset of a neurological deficit fitting a vascular distribution persisting for at least 24 hours and not explained by other etiologies. The modified Rankin (mRankin) score 10 of functional disability at discharge was estimated from medical chart notes. Such estimated mRankin scores are highly correlated with posthospitalization mortality. 11 Poststroke mortality was ascertained through medical chart review, hospital databases, health plan member reporting, Social Security Administration files, and the California State Death Certificate Registry. 12 The sole OAC prescribed was warfarin. Warfarin use at the time of admission was determined from medical chart review. Warfarin prescription at the time of hospital discharge was determined from medical chart review, supplemented by a validated warfarin use algorithm assessing warfarin use after hospitalization. 7 The second study cohort ATRIA-CVRN, has also been described in detail previously. 13 Briefly, the ATRIA-CVRN cohort consists of 33,247 Kaiser Permanente Northern California and Southern California patients aged 21 and older with incident AF or atrial flutter first diagnosed between January 2006 and June 2009 and confirmed by electrocardiography or physician diagnosis in the electronic medical record. A valid diagnosis of AF included one or more inpatient diagnoses or two or more outpatient diagnoses. ATRIA-CVRN included individuals with mitral stenosis or a valve replacement in the mitral or aortic positions (1.5% of the cohort). Emergency department visits for stroke not resulting in hospital admission were included as ATRIA-CVRN outcome events. The same approach was adopted as for ATRIA for reviewing charts, determining mRankin score and warfarin use after hospitalization or an emergency department visit, and validating ischemic stroke events and death. Follow-up continued through June 2009.
The analysis was confined to individuals alive at hospital or emergency department discharge after acute ischemic stroke. For the current study, the date of diagnosis of the first ischemic stroke in the cohort was considered the individual's index date.
Outcome Measures
The primary outcome was prescription of warfarin at the time of hospital discharge after acute ischemic stroke. Participants for whom use of warfarin was planned after discharge were counted as having been discharged with a prescription for warfarin ( Figure 1 ). Secondary outcomes included time to death and recurrent ischemic stroke after discharge for the index stroke.
Covariates
Variables included in the analyses were those hypothesized to be associated with OAC use after ischemic stroke (e.g., prior ischemic stroke, history of heart failure, hypertension, age, diabetes mellitus, vascular disease (coronary artery and peripheral arterial disease), female sex, renal impairment) and those identified as potential contraindications to OAC use (e.g., dementia, prior gastrointestinal or intracranial hemorrhage, poststroke mRankin disability score, race). Information on age and race was obtained from administrative databases. For the ATRIA cohort, information on the remaining covariates was obtained from structured chart review. For the ATRIA-CVRN cohort, information on disability was obtained from chart review, and information on the remaining covariates was obtained from outpatient and inpatient diagnostic codes. 7, 13, 14 For participants not discharged on an OAC, medical record reviewers recorded the specifically stated or clinically apparent reason(s) why an OAC was not prescribed from a list of reasons provided to the reviewer in the ATRIA and ATRIA-CVRN cohorts. If necessary, the reviewer could use a free-text field for reasons not listed. (See Table 3 for list of reasons.) In addition, reviewers were asked to indicate whether there was a plan to prescribe warfarin at some point after discharge. Six hundred nineteen individuals were discharged without warfarin, of whom 95 did not have an explicitly documented or apparent clinical reason for nonprescription of warfarin at discharge. In addition, 22 individuals did not have a documented history of AF in the medical chart during the stroke admission. Although all 22 met study entry criteria for AF, the absence of mention of AF in the record indicated that anticoagulation for AF was not part of the physicians' discharge decision. As a result, 502 individuals with clearly documented reasons for nonuse of warfarin on discharge were included in the analysis of reasons why an OAC was not prescribed at discharge.
Statistical Analysis
A similar percentage of participants were prescribed warfarin at hospital discharge in the two cohorts (43% in the ATRIA cohort, 46% in the ATRIA-CVRN cohort), so the results of the two cohorts were pooled to enhance statistical power. No participants were shared between the two cohorts. For descriptive analyses, chi-square tests were used to compare categorical variables, and Student t-tests were used to compare continuous variables. Univariate and multivariable logistic regression models were used to assess the likelihood of not prescribing OAC therapy on discharge given the presence of clinical features. Fifty-four (3.7%) individuals for whom information on warfarin status after discharge was missing ( Figure 1) were excluded from the analysis. Variables were included in the multivariable models based on clinical and statistical (P < .05) significance. Information on warfarin use at the time of admission for ischemic stroke was included in the analyses. Unadjusted Kaplan-Meier curves were generated for time to recurrent ischemic stroke and time to death according to OAC therapy status on discharge, and statistical significance was assessed using the logrank test. For all analyses, two-sided P < .05 was considered statistically significant. All analyses were conducted using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
The institutional review boards of the collaborating institutions approved the study. Waiver of informed consent was obtained because of the nature of the study.
RESULTS
In the combined ATRIA and ATRIA-CVRN cohorts (n = 46,806), 1,647 (3.5%) individuals were admitted with acute ischemic stroke, 1,459 (88.6%) of whom were discharged alive: 897 from the ATRIA cohort and 562 from the ATRIA-CVRN cohort ( Figure 1 ). Warfarin status at discharge was known for 1,405 (96.3%). Most were aged 75 and older (72.6%), white (80.4%), and female (54.0%). A large proportion of participants had significant comorbidities, including 30.4% with diabetes mellitus, 78.1% with hypertension, 32.7% with coronary disease, and 37.9% with heart failure ( Table 1) . Because of the participants' comorbidities and the fact that they had had a stroke, AF ischemic stroke risk scores were very high (ATRIA: median 10, interquartile range (IQR) 9-11, range 0-15; CHA 2 DS 2 -VASc: median 5, IQR 5-6, range 0-9; and CHADS 2 : median 4, IQR 4-5, range 0-6). Fifty-one percent were discharged with major or severe disability.
Forty-four percent (619/1,405) of participants were discharged without OAC therapy. Discharge without an OAC was much more likely for participants who were not receiving an OAC at admission (59.6% (566/949) vs 11.6% (53/456) with OAC therapy on admission, P < .001). A higher proportion of participants with major or severe disability was discharged without OAC therapy (56.1%) than of those with no or mild disability (31.6%) (P < .001). Seventy-three percent of participants discharged without OAC therapy were prescribed aspirin (Table 1) .
There were strong independent associations between older age, dementia, and disability and nonuse of OAC therapy at discharge. On multivariable analysis, the odds of nonuse of an OAC at discharge for individuals aged 65 to 74 (OR = 3.25, 95% CI = 1.79-5.89) and those aged 75 to 84 (OR = 3.43, 95% CI = 1.98-5.94) was more than three times that of those younger than 65. For those aged 85 and older, the odds of nonuse of OAC at discharge were almost nine times the odds of those younger than 65 (OR = 8.96, 95% CI = 5.01-16.04). Individuals with dementia (OR = 1.69, 95% CI = 1.12-2.57) had a high risk of nonuse of an OAC. In addition, the odds of nonuse of OAC increased with degree of disability poststroke (minor disability: OR = 1.39, 95% CI = 0.77-2.51; major disability: OR = 2.78, 95% CI = 1.53-5.05; severe disability: OR = 12.58, 95% CI = 5.82-27.21 vs no disability. Strong associations were also seen for participants with prior gastrointestinal or intracranial hemorrhage. Even after controlling for multiple clinical features, participants who were admitted without an OAC were far more likely also to be discharged without an OAC (OR = 11.25, 95% CI = 7.95-15.92) ( Table 2) .
Reasons for Nonuse of OAC Therapy
The most commonly cited reasons for not prescribing an OAC on discharge included a perceived high risk of falls (26.7%), poor prognosis (19.3%), prior history of bleeding (17.1%), participant or family refusal (14.9%), older age (11.0%), poor cognitive status (9.4%, n = 47), and risk of hemorrhagic conversion of ischemic stroke (8.8%, n = 44) (Table 3 ). In all, 72% (360/502) of participants not receiving an OAC at discharge had one or more of the following long-term strong contraindications cited: risk of falls, poor prognosis or comfort care only, prior history of bleeding, participant or family refusal, and dementia or poor cognitive status. In this analysis, older age and risk of hemorrhagic conversion were not considered to be strong long-term contraindications.
Postdischarge Death or Recurrent Ischemic Stroke
Not prescribing OAC therapy on discharge was strongly associated with subsequent mortality. Of participants not receiving an OAC at discharge, 21% had died by 30 days after admission, versus 4.6% of those discharged on an OAC (Figure 2A) . By 1 year, the Kaplan-Meier estimate for mortality was 42.5% for those not receiving OAC at discharge versus 19.1% for those receiving an OAC at discharge (P < .001 comparing overall survival curves). The rate of recurrent ischemic stroke was much lower than that for mortality and moderately higher in participants not receiving OAC at discharge (2.1% vs 1.7% at 30 days; 7.7% vs 4.9% at 1 year) (P = .07 comparing unadjusted survival curves over 1 year of follow-up) ( Figure 2B ). Of participants not receiving an OAC at discharge, those categorized as contraindicated because of risk of falls, poor prognosis or comfort care only, prior history of bleeding, participant or family refusal, or dementia or poor cognitive status had 30-day mortality of 26%. By 1 year, 49% had died.
DISCUSSION
Individuals with AF who have had an acute ischemic stroke are at the highest risk of recurrent ischemic stroke. 13 Nonetheless, more than 40% of participants with acute ischemic stroke were discharged without OAC therapy. Of participants who had an ischemic stroke while not on an OAC, almost 60% were discharged without OAC therapy. This large proportion of nonuse of warfarin in these individuals at high risk of stroke occurred in a healthcare system with excellent supports for management of warfarin therapy through dedicated anticoagulation management services. 8 Further, review of medical charts made clear that physicians were aware that an OAC was indicated to prevent stroke in individuals with AF. These results demonstrate that strong contraindications dominate the anticoagulation decision in many older and debilitated individuals with AF, even those at the highest risk of future ischemic stroke. The most commonly cited ongoing reasons for nonuse of OAC therapy on discharge included perceived risk of falls, poor prognosis, prior bleeding, individual or family refusal, and dementia, as well as the lessspecific contraindication of older age. Seventy-two percent (360/502) of participants not receiving an OAC at discharge had one or more of these cited contraindications as the basis for the decision. Multivariable analyses confirmed the strong independent associations between older age, disability, prior bleeding, and dementia and lack of prescription of an OAC at hospital discharge. Nonuse of OAC therapy at admission remained a major determinant of nonuse at discharge, even after accounting for other features related to OACs at discharge. This finding indicates that preadmission contraindications dominated the OAC decision at discharge and suggests that other unmeasured factors added to the documented contraindications. The main reasons cited for nonuse of an OAC were strongly related to mortality, with more than 40% of participants discharged with an OAC dying by 1 year. The rate of recurrent stroke at 1 year in individuals discharged without an OAC was 7.7%, indicating that the vast majority of these individuals died from nonstroke-related comorbidities. Such individuals would have had little opportunity to benefit from the stroke-preventive effects of an OAC.
The most-common reasons for not using an OAC have also been cited in other studies. [15] [16] [17] [18] It is worth Each participant could have more than one reason cited for nonprescription of OAC therapy at discharge. Reasons for nonuse of OACs were specifically stated in the medical chart for 345 (69%) participants; for 157 (31%), reasons were clinically apparent but not specifically stated in the medical chart. a Six hundred nineteen individuals were discharged without warfarin, of whom 95 did not have an explicitly documented or apparent clinical reason for nonprescription of warfarin at discharge. In addition, 22 patients did not have a documented history of AF in the medical chart during their admission for stroke, despite meeting study entry criteria for AF, indicating that anticoagulation for AF was not part of the physicians' discharge decision. As a result, 502 individuals with clearly documented reasons for nonuse of warfarin on discharge were included in this analysis. In Anticoagulation and Risk factors in Atrial Fibrillation (ATRIA), specific reasons listed under other included improving exam, visual disturbance, no evident benefit to anticoagulation, not a good candidate, not an anticoagulation candidate, and rare episodes of paroxysmal atrial fibrillation. In ATRIA Cardiovascular Research Network, reasons listed under other included outpatient physicians had previously decided not to anticoagulate and aspirin alone recommended by neurology consult for unknown reasons. INR = international normalized ratio. considering whether they should serve as strong contraindications and whether they can be mitigated. Certainly, poor prognosis, if assessed accurately, is a reasonable contraindication; a short remaining lifespan would make benefit from an OAC unlikely. Prior bleeding with risk of recurrence is another common strong contraindication for an OAC. Although the expected strokepreventive benefit from OAC treatment outweighs the harm from nearly all extracranial hemorrhages, most people do not restart an OAC after a major bleeding event. 19 The most commonly cited reason for not prescribing OAC therapy was high risk of falls. Physicians are concerned that anticoagulants will aggravate trauma after falls, particularly head trauma. 20 A recent large database study highlighted the high incidence of anticoagulant-associated intracranial hemorrhage, fall related and otherwise, in older U.S. veterans with AF, and another recent study reported mortality of 6% for individuals with AF taking an OAC after a ground-level fall. 21, 22 In contrast, one older modeling study estimated that an individual would have to fall up to 295 times per year before the risks of anticoagulation would outweigh the benefits. 23 In any case, physician reluctance to use an OAC in individuals at high risk of falling is understandable. Formal fall risk assessment and interventions to reduce fall risk might increase the use of OACs in frail elderly adults. 24, 25 Older adults with AF are less likely to be treated with an OAC despite good evidence that they gain substantial net benefit from anticoagulants. 26, 27 Bleeding risk increases with age, but so does the risk of ischemic stroke and the potential benefits of OAC therapy. [27] [28] [29] Older age as a contraindication may be a synonym for frailty, but for robust elderly adults, age alone should not be considered a valid contraindication to OAC therapy.
Cognitive impairment was a reason for nonuse of OAC therapy in 9% of participants. Previous studies have reported similar underuse of OAC therapy in individuals with cognitive impairment. 15, 30 Use of anticoagulant therapy in this population can be challenging, but in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events, Mini-Mental State Examination score was not associated with risk of vascular events or major hemorrhage. 31 Such findings indicate that warfarin, and presumably newer anticoagulants, can be administered to individuals with dementia under appropriate supervision.
The proportion of individuals with AF treated with an OAC has not increased substantially in recent years despite the introduction of novel anticoagulants that are easier to take and have a lower risk of intracranial hemorrhage 32 as well as the substantial attention to AF stroke prevention in the lay and professional media. [33] [34] [35] In a recent report from an AF registry based in cardiology practices, less than half of high-risk individuals received an OAC. 36 A recent Swedish study of administrative databases reported similarly low rates of OAC uptake in individuals with AF after ischemic stroke; only 35% of participants received an OAC within 3 months of discharge. The current study demonstrates that, even in individuals with AF at the highest risk of ischemic stroke, there are large subgroups with major and complex contraindications to anticoagulant therapy consistent with the predominantly older age of individuals with AF. 37 Although some of these contraindications may be addressable, it is likely that a significant fraction of individuals with AF will remain untreated with anticoagulants.
This study benefitted from its large size, a detailed chart review protocol that included questions explicitly addressing contraindications to OAC use at discharge, and follow-up for stroke and death after discharge all within well-studied community-based cohorts of individuals with AF with high-quality ascertainment of use of anticoagulants. A real-time survey exploring physician reasons for not prescribing OAC therapy would have been preferable to the retrospective chart review, but such a study would be difficult to implement on a large scale and would be at risk of low response rate. Finally, the data reflect OAC decisions before the era of novel anticoagulants. It is conceivable that some individuals not treated with warfarin might now be treated with a novel agent, although recent prescription data suggest that novel anticoagulants are replacing warfarin but not increasing the proportion of individuals with AF treated with anticoagulants. 34 Novel anticoagulants led to fewer intracranial hemorrhages than warfarin in randomized trials, 32, 38 although these trials were less likely to enroll very old, frail, and fall-prone individuals. As a result, the relative safety of novel anticoagulants in such individuals with AF is currently not clear and is an important area for future investigation. 21, 32, 38, 39 
CONCLUSION
Despite the high risk of recurrent stroke that individuals with AF who have had an acute ischemic stroke face, more than 40% of study participants were not discharged on OAC therapy. The dominant reasons for nonuse of an OAC were risk of falls, poor prognosis or comfort care only, prior history of bleeding, participant or family refusal, older age, and dementia or poor cognitive status. These data suggest that more work is needed in this highrisk population to improve outcomes and individual care decisions regarding anticoagulation. Future work should focus on strategies to mitigate fall risk, improve assessment of risks and benefits of anticoagulation in individuals with AF, and determine whether newer anticoagulants are safer in complex elderly and frail individuals.
